Liquid Biopsy CfDNA EGFR Test sale cost 4510 AED
IgVH Hypermutation Analysis Confirmatory Test sale cost 4680 AED IgVH Hypermutation Analysis Confirmatory Test 5,200 د.إ Original price was: 5,200 د.إ.4,680 د.إCurrent price is: 4,680 د.إ.
Chronic Lymphocytic Leukemia CLL Prognostic Panel Test sale cost 4210 AED Chronic Lymphocytic Leukemia CLL Prognostic Panel Test 4,680 د.إ Original price was: 4,680 د.إ.4,210 د.إCurrent price is: 4,210 د.إ.
Sale!

Liquid Biopsy CfDNA EGFR Test

Original price was: 5,010 د.إ.Current price is: 4,510 د.إ.

-10%

The Liquid Biopsy cfDNA EGFR Test is a cutting-edge diagnostic procedure available at DNA Labs UAE, designed to detect the presence of specific mutations in the epidermal growth factor receptor (EGFR) gene within circulating free DNA (cfDNA) found in a patient’s blood. This non-invasive test is particularly vital for individuals with non-small cell lung cancer (NSCLC), as it helps in identifying mutations in the EGFR gene that may influence treatment choices and outcomes. By analyzing cfDNA, the test can provide crucial information without the need for a traditional tissue biopsy, which can be invasive and challenging in certain cases.

The process involves a simple blood draw, after which the sample is analyzed using advanced genomic sequencing technologies to detect EGFR gene mutations. This approach allows for real-time monitoring of tumor dynamics, detection of resistance mutations that may develop during treatment, and aids in the selection of targeted therapies that are more likely to be effective based on the genetic makeup of the cancer.

Priced at 4510 AED, the Liquid Biopsy cfDNA EGFR Test offered by DNA Labs UAE represents a significant advancement in personalized cancer care, offering a less invasive, quicker, and often more feasible option for obtaining vital genetic information that can guide treatment decisions and improve patient outcomes.

Home  Sample collection service available

  • 100% accuaret Test Results
  • Ranked as Most trusted Genetic DNA Lab
  • This test is not intended for medical diagnosis or treatment
Guaranteed Safe Checkout

LIQUID BIOPSY CfDNA EGFR Test

Test Name: LIQUID BIOPSY CfDNA EGFR Test

Components: For Colorectal & Lung Cancer: *p.E746_A750 deletion, *p.T790M mutation, *p.L858R mutation

Price: 4510.0 AED

Sample Condition: 10 mL whole blood in 1 Streck tube. Ship refrigerated. DO NOT FREEZE. Clinical history is mandatory.

Report Delivery: Sample Mon / Thu by 9 am; Report Fri / Tue

Method: Droplet Digital PCR

Test Type: Cancer

Doctor: Oncologist

Test Department: MOLECULAR DIAGNOSTICS

Pre Test Information: Clinical history is mandatory.

Test Details:

Liquid biopsy cfDNA EGFR testing is a type of genetic testing that is used to identify specific mutations in the epidermal growth factor receptor (EGFR) gene in circulating cell-free DNA (cfDNA) samples. This type of testing is commonly used in the field of oncology to guide treatment decisions for patients with non-small cell lung cancer (NSCLC) who have EGFR mutations.

Liquid biopsy refers to the analysis of genetic material, such as DNA, that is found in bodily fluids like blood. In the case of cfDNA EGFR testing, a blood sample is taken from the patient and the cfDNA is isolated and analyzed for specific mutations in the EGFR gene.

EGFR mutations are important in NSCLC because they can affect how cancer cells grow and respond to certain treatments. The cfDNA EGFR test can detect various EGFR mutations, including the most common ones such as exon 19 deletions and exon 21 L858R substitutions. Identifying these mutations is crucial for determining the most appropriate treatment options for patients with NSCLC. For example, patients with certain EGFR mutations may benefit from targeted therapies, such as EGFR tyrosine kinase inhibitors (TKIs), which specifically target cancer cells with these mutations.

Compared to traditional tissue biopsies, liquid biopsy cfDNA EGFR testing offers several advantages. It is a non-invasive procedure that can be easily repeated over time to monitor treatment response and detect any emerging resistance mutations. Liquid biopsy also allows for a more comprehensive analysis of tumor heterogeneity, as it can capture genetic changes from different tumor sites that may not be accessible through tissue biopsies.

In summary, liquid biopsy cfDNA EGFR testing is a valuable tool in the field of oncology for identifying EGFR mutations in patients with NSCLC. It helps guide treatment decisions and monitor treatment response, offering a less invasive and more comprehensive approach compared to traditional tissue biopsies.

Test Name LIQUID BIOPSY CfDNA EGFR Test
Components For Colorectal & Lung Cancer:*p.E746_A750 deletion*p.T790M mutation *p.L858R mutation
Price 4510.0 AED
Sample Condition 10 mL whole blood in 1 Streck tube. Ship refrigerated. DO NOT FREEZE. Clinical history is mandatory.
Report Delivery Sample Mon / Thu by 9 am; Report Fri / Tue
Method Droplet Digital PCR
Test type Cancer
Doctor Oncologist
Test Department: MOLECULAR DIAGNOSTICS
Pre Test Information Clinical history is mandatory.
Test Details

Liquid biopsy cfDNA EGFR testing is a type of genetic testing that is used to identify specific mutations in the epidermal growth factor receptor (EGFR) gene in circulating cell-free DNA (cfDNA) samples. This type of testing is commonly used in the field of oncology to guide treatment decisions for patients with non-small cell lung cancer (NSCLC) who have EGFR mutations.

Liquid biopsy refers to the analysis of genetic material, such as DNA, that is found in bodily fluids like blood. In the case of cfDNA EGFR testing, a blood sample is taken from the patient and the cfDNA is isolated and analyzed for specific mutations in the EGFR gene. EGFR mutations are important in NSCLC because they can affect how cancer cells grow and respond to certain treatments.

The cfDNA EGFR test can detect various EGFR mutations, including the most common ones such as exon 19 deletions and exon 21 L858R substitutions. Identifying these mutations is crucial for determining the most appropriate treatment options for patients with NSCLC. For example, patients with certain EGFR mutations may benefit from targeted therapies, such as EGFR tyrosine kinase inhibitors (TKIs), which specifically target cancer cells with these mutations.

Compared to traditional tissue biopsies, liquid biopsy cfDNA EGFR testing offers several advantages. It is a non-invasive procedure that can be easily repeated over time to monitor treatment response and detect any emerging resistance mutations. Liquid biopsy also allows for a more comprehensive analysis of tumor heterogeneity, as it can capture genetic changes from different tumor sites that may not be accessible through tissue biopsies.

In summary, liquid biopsy cfDNA EGFR testing is a valuable tool in the field of oncology for identifying EGFR mutations in patients with NSCLC. It helps guide treatment decisions and monitor treatment response, offering a less invasive and more comprehensive approach compared to traditional tissue biopsies.

SKU: TEST-4639 Category:

Related products